Cartesian Therapeutics (RNAC) Operating Leases (2018 - 2026)

Cartesian Therapeutics (RNAC) has 9 years of Operating Leases data on file, last reported at $7.7 million in Q1 2026.

• On a quarterly basis, Operating Leases fell 45.48% year-over-year to $7.7 million in Q1 2026; TTM through Mar 2026 was $7.7 million, a 45.48% decrease from a year earlier, with the FY2025 full-year figure at $8.5 million, down 23.43% from the prior year.
• Operating Leases for Q1 2026 stood at $7.7 million, down from $8.5 million in the prior quarter.
• Over the last five years, Operating Leases for RNAC reached as high as $14.1 million in Q1 2025 and fell as low as $3.2 million in Q4 2022.
• Historically, Operating Leases has averaged $9.7 million across 5 years, with a median of $9.2 million in 2023.
• Across the five-year window, Operating Leases tumbled 62.78% in 2022 and jumped 174.66% in 2023, its largest moves.
• Year by year, Operating Leases stood at $3.2 million in 2022, then soared by 174.66% to $8.8 million in 2023, then advanced by 26.67% to $11.1 million in 2024, then dropped by 23.43% to $8.5 million in 2025, then declined by 10.04% to $7.7 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $7.7 million in Q1 2026, $8.5 million in Q4 2025, and $8.7 million in Q3 2025.